芬妥木单抗

芬妥木单抗
单克隆抗体
种类完整抗体
目標IGF-1受体
臨床資料
ATC碼
  • 未分配
法律規範狀態
法律規範
  • 实验性
识别信息
CAS号943453-46-1  ☒N
ChemSpider
  • none
UNII
KEGG
化学信息
化学式C6462H9948N1736O2020S54
摩尔质量146,008.04 g·mol−1

芬妥木单抗（INN：Figitumumab；开发代号：CP-751871）是一种针对胰岛素样生长因子1受体的单克隆抗体，[1]已被研究用于治疗多种癌症，例如肾上腺皮质癌（英语：Adrenocortical carcinoma）[2]和非小细胞肺癌（英语：Non-small-cell lung cancer）。[3]

这种药物由辉瑞公司开发，但他们于2011年1月停止了该药物的开发并停止了生产。[4]

临床试验

第一个III期试验（针对非小细胞肺癌）因死亡人数过多而于2009年12月暂停，[5]但其他试验仍在继续。[6][7]

它将被纳入I-SPY2乳腺癌试验中。[8]

参考资料

  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Figitumumab （页面存档备份，存于互联网档案馆）, American Medical Association.
  2. ^ Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemotherapy and Pharmacology. March 2010, 65 (4): 765–73. PMC 2875253 可免费查阅. PMID 19649631. doi:10.1007/s00280-009-1083-9. 
  3. ^ Gualberto A, Karp DD. Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clinical Lung Cancer. July 2009, 10 (4): 273–80. PMID 19632947. doi:10.3816/CLC.2009.n.038. 
  4. ^ Cancer sufferer fears future without 'life-saver' drug. BBC News. July 2014 [2024-01-22]. （原始内容存档于2015-09-25）. 
  5. ^ Krauskopf L. Pfizer ends late-stage lung-cancer study. Reuters. 29 December 2009 [2024-01-22]. （原始内容存档于2010-02-26）. 
  6. ^ Clinical trial number NCT00976508 for "Figitumumab Combined With Pegvisomant For Advanced Solid Tumors" at ClinicalTrials.gov
  7. ^ Clinical trial number NCT00635245 for "CP-751871 in Treating Women With Early-Stage Breast Cancer That Can Be Removed by Surgery" at ClinicalTrials.gov
  8. ^ Breast cancer study aims to speed drugs, cooperation. Reuters. March 2010 [2024-01-22]. （原始内容存档于2010-03-22）.